Briefing
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
Baseline ctDNA-negativity was associated with longer RFS than positivity (event rate 20.9% [23/110] vs 80.0% [12/15]; HR 0.150, 95% CI 0.073-0.306). In the mRNA-4157/V940 plus pembrolizumab arm, RFS event rates were 10.4% (8/77) if negative vs 76.9% (10/13) if positive (HR 0.087). The pembrolizumab monotherapy comparison used only 2 ctDNA-positive patients.
- Design: LBA
- n: 125 patients with evaluable baseline ctDNA; 110 (88%) ctDNA-negative at start of treatment
- Assay: RaDaR (as stated in prior reports of this analysis; confirm brand is named in this abstract body if cited as such)